Project Grant R44DA059523
Award Date
9/15/23
Completion Date
8/31/24
Dollars Obligated
$318K
Federal Agency
National Institute on Drug Abuse
Awardee
Cari Health, Inc. (NE1LFLNBCUG7)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for the development of a novel liquid methadone dispensing device and smart container system called the MOUD-EID. The total funding amount is $319,000 and the project period is from August 1, 2024 to July 31, 2025. The key products/services to be delivered include: (A) an inner container with electromechanical valves to precisely dispense up to...
The National Institute on Drug Abuse (NIDA) awarded a $636,344 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Cari Health, Inc. (doing business as Clinical Addiction Recovery Institute) to develop and commercialize a new science-based approach for methadone dosing adjustments. The project aims to use novel, non-invasive point-of-care technology to evaluate small blood samples and quickly determine an individual patient's methadone rate of metabolism,...
The National Institute on Drug Abuse (NIDA) awarded Labsys LLC a $643,948 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, painless patch that uses microneedle technology to monitor medication levels in the interstitial fluid and provide real-time insights into treatment effectiveness. In Phase I, the team will engineer an alpha prototype...
This $586,936 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a low-cost, disposable point-of-use urine test strip for the rapid quantification of substance use disorder (SUD) medication drugs and their metabolites. The goal is to create an innovative lateral flow assay with signal amplification capabilities to enable highly sensitive and specific detection of drugs like...
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Tenvos Inc., a minority-owned and woman-owned technology company. The grant will support the development of a software-based medical device (SAMD) integrated into a smartphone application that can detect opioid use through voice analysis. The proposed solution aims to enable patients in outpatient opioid use disorder (OUD) treatment to remotely test for...
The National Institute on Drug Abuse (NIDA), through its Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $399,589 Project Grant to Resilient Lifescience, Inc. The purpose of this grant, awarded on Sep 15, 2024, is to develop a wearable medical device to detect opioid overdose. The project is expected to be completed by Aug 31, 2025. The Drug Use and Addiction Research Programs support a wide range of research activities related to substance use disorders, addiction, and related...
This $1,076,018 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a randomized clinical trial of DCH-003, a digital therapeutic developed by Dynamicare Health Inc. to deliver contingency management (CM) for the treatment of stimulant use disorder. The study aims to evaluate the efficacy of DCH-003, which automates CM through remote, self-administered saliva tests and integrates evidence-based therapy...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and pilot testing of a methadone loading dose approach to initiate treatment for fentanyl opioid use disorder (OUD) among hospitalized patients. The $194,903 award, effective April 15, 2025 through March 31, 2030, will enable the principal investigator, Dr. Ashish Thakrar, to conduct a dose-finding study to identify...
This $810,668 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on evaluating an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to demonstrate the feasibility of DRHQ, which is moving from the lead optimization stage into preclinical development. The research will be conducted by Virogenomics...
This Project Grant award, with a total funding amount of $958,629, was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support the real-world adoption of an innovative digital health therapeutic called KIOS, which uses nonlinear control theory to track multiple symptoms (e.g., craving, mood, pain) and deliver personalized, evidence-based intervention strategies to patients with opioid use disorder...